TY - JOUR
T1 - The relationship between expression of EGFR, MMP-9, and C-erbB-2 and survival time in resected non-small cell lung cancer
AU - Lee, Seung Heon
AU - Jung, Jin Yong
AU - Lee, Kyoung Ju
AU - Lee, Seung Hyeun
AU - Kim, Se Joong
AU - Ha, Eun Sil
AU - Lee, Eun Joo
AU - Hur, Gyu Young
AU - Jung, Ki Hwan
AU - Jung, Hye Cheol
AU - Lee, Sung Yong
AU - Kim, Je Hyeong
AU - Lee, Sang Yeub
AU - Shin, Chol
AU - Shim, Jae Jeong
AU - In, Kwang Ho
AU - Kang, Kyung Ho
AU - Yoo, Se Hwa
AU - Kim, Chul Hwan
PY - 2005/9
Y1 - 2005/9
N2 - Background: Non-small cell lung cancer (NSCLC) is a common cause of cancer-related death in North America and Korea, with an overall 5-year survival rate of between 4 and 14% The TNM staging system is the best prognostic index for operable NSCLC. However, epidermal growth factor receptor (EGFR), matrix metalloproteinase-9(MMP-9), and C-erbB-2 have all been implicated in the pathogenesis of NSCLC and might provide prognostic information. Methods: Immunohistochemical staining of 81 specimens from a resected primary non-small cell lung cancer was evaluated in order to determine the role of the biological markers on NSCLC. Immunohistochemical staining for EGFR, MMP-9, and C-erbB-2 was performed on paraffin-embedded tissue sections to observe the expression pattern according to the pathologic type and surgical staging. The correlations between the expression of each biological marker and the survival time was determined. Results: When positive immunohistochemical staining was defined as the extent area>20%(more than Grade 2), the positive rates for EGFR, MMP-9, and C-erbB-2 staining were 71.6%, 44.3%, and 24.1% of the 81 patients, respectively. The positive rates of EGFR and MMP-9 stain for NSCLC according to the surgical stages I, II, and IIIa were 75.0% and 41.7%, 66.7% and 47.6%, and 76.9% and 46.2%, respectively. The median survival time of the EGFR(-) group, 71.8 months, was significantly longer than that of the EGFR(+) group, 33.5 months.(p=0.018, Kaplan-Meier Method, log-rank test). The MMP-9(+) group had a shorter median survival time than the MMP-9(-) group, 35.0 and 65.3 months, respectively (p=0.2). The co-expression of EGFR and MMP-9 was associated with a worse prognosis with a median survival time of 26.9 months , when compared with the 77 months for both negative-expression groups (p=0.0023). There were no significant differences between the C-erbB-2(+) and C-erbB-2 (-) groups. Conclusion: In NSCLC, the expression of EGFR might be a prognostic factor, and the co expression of EGFR and MMP-9 was found to be associated with a poor prognosis. However, C-erbB-2 expression had no prognostic significance.
AB - Background: Non-small cell lung cancer (NSCLC) is a common cause of cancer-related death in North America and Korea, with an overall 5-year survival rate of between 4 and 14% The TNM staging system is the best prognostic index for operable NSCLC. However, epidermal growth factor receptor (EGFR), matrix metalloproteinase-9(MMP-9), and C-erbB-2 have all been implicated in the pathogenesis of NSCLC and might provide prognostic information. Methods: Immunohistochemical staining of 81 specimens from a resected primary non-small cell lung cancer was evaluated in order to determine the role of the biological markers on NSCLC. Immunohistochemical staining for EGFR, MMP-9, and C-erbB-2 was performed on paraffin-embedded tissue sections to observe the expression pattern according to the pathologic type and surgical staging. The correlations between the expression of each biological marker and the survival time was determined. Results: When positive immunohistochemical staining was defined as the extent area>20%(more than Grade 2), the positive rates for EGFR, MMP-9, and C-erbB-2 staining were 71.6%, 44.3%, and 24.1% of the 81 patients, respectively. The positive rates of EGFR and MMP-9 stain for NSCLC according to the surgical stages I, II, and IIIa were 75.0% and 41.7%, 66.7% and 47.6%, and 76.9% and 46.2%, respectively. The median survival time of the EGFR(-) group, 71.8 months, was significantly longer than that of the EGFR(+) group, 33.5 months.(p=0.018, Kaplan-Meier Method, log-rank test). The MMP-9(+) group had a shorter median survival time than the MMP-9(-) group, 35.0 and 65.3 months, respectively (p=0.2). The co-expression of EGFR and MMP-9 was associated with a worse prognosis with a median survival time of 26.9 months , when compared with the 77 months for both negative-expression groups (p=0.0023). There were no significant differences between the C-erbB-2(+) and C-erbB-2 (-) groups. Conclusion: In NSCLC, the expression of EGFR might be a prognostic factor, and the co expression of EGFR and MMP-9 was found to be associated with a poor prognosis. However, C-erbB-2 expression had no prognostic significance.
KW - C-erbB-2
KW - EGFR
KW - MMP-9
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=26944480423&partnerID=8YFLogxK
U2 - 10.4046/trd.2005.59.3.286
DO - 10.4046/trd.2005.59.3.286
M3 - Article
AN - SCOPUS:26944480423
SN - 1738-3536
VL - 59
SP - 286
EP - 297
JO - Tuberculosis and Respiratory Diseases
JF - Tuberculosis and Respiratory Diseases
IS - 3
ER -
